RecruitingAdvanced LeiomyosarcomaAdipocytic SarcomaAdvanced Liposarcoma
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
Sponsor: Washington University School of Medicine
You may qualify if…
- ✓ Pathologically proven diagnosis of unresectable or metastatic leiomyosarcoma or adipocytic sarcoma.
- ✓ Progressed on at least 1 line of prior therapy and have received no more than 4 lines of prior therapy.
- ✓ Measurable disease per RECIST 1.1.
- ✓ At least 18 years of age.
- ✓ ECOG performance status ≤ 1
- ✓ Adequate bone marrow and organ function within 14 days before first dose of study treatment as defined below:
- ✓ Absolute neutrophil count ≥ 1.5 K/cumm without granulocyte colony-stimulating factor support within 2 weeks of collection
- ✓ Platelets ≥ 100 K/cumm without transfusion within 2 weeks of collection
You may not qualify if…
- ✕ Pure well-differentiated liposarcoma or low grade leiomyosarcoma.
- ✕ Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
- ✕ Prior treatment with zanzalintinib.
- ✕ Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.
- ✕ Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.
- ✕ Radiation therapy for bone metastasis within 2 weeks before first dose of study treatment; any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
- ✕ Currently receiving any other investigational agents.
- ✕ Patients with untreated brain metastases. Patients with treated brain metastases are allowed if post-treatment brain-imaging after CNS-directed therapy shows no evidence of progression and disease is stable for at least 4 weeks before first dose of study treatment.
Where it's recruiting
Missouri
St Louis
Source: ClinicalTrials.gov · NCT06957431 · last updated 2026-06-03